Born to survive: how cancer cells resist CAR T cell therapy
Abstract Although chimeric antigen receptor T cells demonstrated remarkable efficacy in patients with chemo-resistant hematologic malignancies, a significant portion still resist or relapse. This immune evasion may be due to CAR T cells dysfunction, a hostile tumor microenvironment, or resistant can...
Guardado en:
Autores principales: | Jean Lemoine, Marco Ruella, Roch Houot |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/160e195e48c640ac9e65ed6f10b77e15 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients
por: Angelo Maiolino, et al.
Publicado: (2021) -
CAR T-CELL
por: Francesco Saglio
Publicado: (2021) -
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia
por: Adriana Seber, et al.
Publicado: (2021) -
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma
por: Alvaro J. Alencar, et al.
Publicado: (2021) -
The Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular seeks the implementation of, and access to, the CAR-T cell treatment in Brazil
por: Dante Mário Langhi Junior, et al.
Publicado: (2021)